Held to a manufacturer's standard.

Why physicians choose BioRegenEx

The regenerative medicine supply market grew faster than its documentation did. Material has been sold on particle counts that were never independently verified, from tissue sources that were never disclosed, shipped without temperature control. The practical result is that a physician has had no reliable way to compare two vials. Everything below exists to answer that.

Quality standards

Characterization happens before release, not on request. Every lot is measured by nanoparticle tracking analysis for particle count and size distribution, confirmed for the exosome identity markers CD9, CD63 and CD81, and screened for sterility, mycoplasma and endotoxin. Those results are issued on a Certificate of Analysis by an independent laboratory — the distinction that matters, because in-house numbers are not verification. Temperature-controlled logistics carry the material from the facility to delivery, and the storage window is published rather than implied: sterile saline vials at −80 °C for 18 months, or a standard freezer for up to 3 months.

Scientific transparency

BioRegenEx maintains an indexed library of 229 distinct peer-reviewed publications on MSC-derived exosomes, every entry linked to its primary source on PubMed. Human clinical studies are listed first within each category, and studies reporting null or mixed results are included rather than filtered out — a library that only contains good news is a marketing document, not a literature review. The library is machine-readable as well as human-readable, so a claim made anywhere on this site can be traced back to a specific paper.

Browse the research library · How exosomes signal · How characterization is done

Source transparency

The tissue source is Wharton's Jelly from donated, consented, screened full-term umbilical cord tissue — named plainly, from a single source, with no embryonic material at any stage. "Perinatal" is not a source; it is a way of avoiding naming one. Chain of custody and batch records are maintained for every lot, and the manufacturing partner operates a sterile, ISO-classified facility under processes consistent with 21 CFR Parts 210, 211 and 600.

Why the source matters · How sources differ

Physician support

Documentation requests, handling and storage guidance, and technical questions are handled directly rather than routed through a sales script. Educational material is written for the person who has to defend the decision — including the material that explains what this category cannot claim.

Request documentation · How to read a COA · Storage and handling

How to evaluate any exosome supplier

These are the questions worth asking of every supplier in this category, BioRegenEx included. They are published here because a supplier that will not answer them is the finding.

Who made it?	Is the supplier the manufacturer or a distributor? Either is legitimate. Being unclear about which is not.
What is in the vial?	Particle count and size by NTA, identity markers confirmed, sterility, mycoplasma and endotoxin — per lot, not per product line.
Who did the testing?	An independent laboratory, or the seller? A self-issued COA verifies nothing.
What is the tissue source?	A specific named tissue from screened, consented donors. Not a blend, and not a vague category.
How was it shipped and stored?	Temperature-controlled, with a stated storage window. Material mishandled on arrival is not the material that was tested.
What does the evidence show?	Primary citations you can open, including studies with null or mixed findings.
What is claimed?	Any supplier claiming FDA approval, or implying that facility registration is approval, is describing a regulatory posture that does not exist.

The full checklist · Red flags · FDA-registered vs FDA-approved

Questions physicians ask before ordering

Does BioRegenEx manufacture its own exosomes?

No. BioRegenEx is a distributor. The material is manufactured under cGMP-aligned processes in an FDA-registered U.S. facility by a manufacturing partner that BioRegenEx qualifies and audits on documentation. Being explicit about this matters: a supplier that blurs the line between distributing and manufacturing is usually blurring other lines too.

Is BioRegenEx a medical practice?

No. BioRegenEx operates no clinics, employs no treating physicians, administers no therapy, and does not sell to consumers. It supplies characterized material and the documentation that describes it to licensed physicians, clinics, and researchers.

What testing appears on the Certificate of Analysis?

Particle count and size distribution by nanoparticle tracking analysis (NTA), exosome identity markers CD9, CD63 and CD81, sterility, mycoplasma screening, and endotoxin by LAL assay. Results are issued by an independent laboratory rather than self-reported, and a COA accompanies every lot.

What tissue source is used, and how is it screened?

Wharton's Jelly from donated, consented, screened full-term umbilical cord tissue. It is a single disclosed source, not a blend, and it is not described vaguely as perinatal. No embryonic material is involved at any stage.

How should the material be stored on arrival?

Sterile saline vials are stable at minus 80 degrees Celsius for 18 months, or in a standard freezer for up to 3 months. Storage requirements are stated plainly because a product mishandled on arrival is no longer the product that was tested.

Are exosome products FDA approved?

No. There are no FDA-approved exosome products of any kind, from any supplier. BioRegenEx material is supplied for research use only. FDA-registered facility means the facility is listed with the FDA as required for certain manufacturing activities — it is not an approval, a clearance, or an evaluation of any product made there, and the two are routinely conflated in this category.

Can I review documentation before ordering?

Yes. A sample Certificate of Analysis and characterization data are available for your team or compliance reviewer to examine before any order is placed. Any supplier unwilling to provide this before a purchase is telling you something.

What BioRegenEx does not claim

MSC-derived exosome products are not approved by the U.S. Food and Drug Administration for the treatment of any disease or condition. BioRegenEx material is supplied for research use only, and BioRegenEx makes no representation that it diagnoses, treats, cures, or prevents any disease. That position is not a disclaimer appended to a sales page — it determines what BioRegenEx supplies, to whom, and how it is described.